Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

[1]  A. Oza,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[2]  I. Ray-Coquard,et al.  Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. , 2020, The Lancet. Haematology.

[3]  A. Oza,et al.  Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons? , 2020, Cancers.

[4]  R. Wenham,et al.  Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Mouret-Reynier,et al.  EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. , 2019, Journal of Clinical Oncology.

[6]  A. Reuss,et al.  Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883) , 2019, Journal of Medical Genetics.

[7]  A. Tinker,et al.  Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. , 2019, Gynecologic oncology.

[8]  G. Lenhart,et al.  Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. , 2018, Gynecologic oncology.

[9]  V. Gebski,et al.  Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. , 2018, The Lancet. Oncology.

[10]  K. Moore,et al.  Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. , 2017, Gynecologic oncology.

[11]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[12]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[13]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[14]  A. Reuss,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Lux,et al.  A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) , 2016, Journal of Cancer Research and Clinical Oncology.

[16]  D. Matei,et al.  Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer , 2016, British Journal of Cancer.

[17]  H. Cohen,et al.  NCCN Guidelines ® Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines , 2016 .

[18]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[19]  C. U. Uyl‐de Groot,et al.  Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  J. Daurès,et al.  Under-treatment of elderly patients with ovarian cancer: a population based study , 2015, BMC Cancer.

[21]  A. Abernethy,et al.  Patient preferences in advanced or recurrent ovarian cancer , 2014, Cancer.

[22]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[23]  R. Zeillinger,et al.  Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium , 2013, Journal of Ovarian Research.

[24]  John Brazier,et al.  Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[26]  P. Harter,et al.  Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience , 2012, Oncology Research and Treatment.

[27]  D. Katsaros,et al.  Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. , 2009, Critical reviews in oncology/hematology.

[28]  G. Vlastos,et al.  Older female cancer patients: importance, causes, and consequences of undertreatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Mayne,et al.  Myelodysplastic syndromes , 2007, Cancer.

[30]  S. Loibl,et al.  Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.